Technical Analysis for KALV - KalVista Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 29.29 3.79% 1.07
KALV closed up 7.18 percent on Tuesday, March 19, 2019, on 86 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical KALV trend table...

Date Alert Name Type % Chg
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup 3.79%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.79%
Mar 19 Upper Bollinger Band Walk Strength 3.79%
Mar 19 Inside Day Range Contraction 3.79%
Mar 19 Wide Bands Range Expansion 3.79%
Mar 18 Volume Surge Other 11.24%
Mar 18 Upper Bollinger Band Walk Strength 11.24%
Mar 18 Wide Bands Range Expansion 11.24%
Mar 18 Upper Bollinger Band Touch Strength 11.24%
Mar 15 Jack-in-the-Box Bullish Bullish Swing Setup 1.17%

Older signals for KALV ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Medical Specialties Pharmaceutical Diseases Organ Systems Enzymes Hereditary Angioedema Diabetic Macular Edema Angioedema Protease Inhibitor
Is KALV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 34.92
52 Week Low 7.73
Average Volume 107,771
200-Day Moving Average 16.9375
50-Day Moving Average 20.705
20-Day Moving Average 23.644
10-Day Moving Average 25.27
Average True Range 2.1751
ADX 43.09
+DI 40.4581
-DI 11.8365
Chandelier Exit (Long, 3 ATRs ) 28.3947
Chandelier Exit (Short, 3 ATRs ) 26.0253
Upper Bollinger Band 29.455
Lower Bollinger Band 17.833
Percent B (%b) 0.89
BandWidth 49.154119
MACD Line 2.0788
MACD Signal Line 1.5503
MACD Histogram 0.5285
Fundamentals Value
Market Cap 274.09 Million
Num Shares 9.71 Million
EPS -3.07
Price-to-Earnings (P/E) Ratio -9.19
Price-to-Sales 202.03
Price-to-Book 4.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.79
Resistance 3 (R3) 30.70 29.76 30.36
Resistance 2 (R2) 29.76 29.11 29.80 30.21
Resistance 1 (R1) 28.99 28.70 29.38 29.08 30.07
Pivot Point 28.05 28.05 28.24 28.09 28.05
Support 1 (S1) 27.28 27.40 27.67 27.37 26.37
Support 2 (S2) 26.34 26.99 26.38 26.23
Support 3 (S3) 25.57 26.34 26.08
Support 4 (S4) 25.66